Innovate UK

Results of Competition:	Viral Vector Manufacturing for Cell and Gene Therapies - Challenge Fund
Competition Code:	1710_HLS_VVM

Total available funding is £16m

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
Cobra Biologics Ltd	Embeding & Securing Commercial Viral Vector Production within a CDMO environment	£5,153,000	£2,576,500

Project description - provided by applicants

Cell and Gene therapy products are changing the lives of patients receiving treatment as part of early stage clinical trials. There is a clear need for Cobra Biologics, and the UK, to increase capacity and capability to provide a rapid approach for the production of viral vector material to support both clinical trials and commercial in-market supply. This project to support expansion at Cobra Biologics (Keele, UK) will give the UK world leading capabilities for clinical and commercial production of gene therapy viral vectors. The project will form part of a larger investment made by Cobra to enhance the development and the manufacturing the viral vector products in the UK. The resulting capacity and capability enhancements will support existing and new customers' clinical and commercial ambitions, leading to more innovative Gene Therapy medicines reaching patients. Furthermore, it will add to and work with the existing infrastructure in the UK for the translation of these innovative medicines from academic interests to commercial reality. The outcome will be to establish Cobra Biologics, and the UK, as an internationally recognised centre of excellence in the field, and establish commercial viral vector manufacturing capability within the UK.

Note: you can see all Innovate UK-funded projects here

https://www.gov.uk/government/publications/innovate-uk-funded-projects_Use the Competition Code given above to search for this competition's results

Innovate UK

Results of Competition:	Viral Vector Manufacturing for Cell and Gene Therapies - Challenge Fund
Competition Code:	1710_HLS_VVM

Total available funding is £16m

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
Oxford BioMedica UK Limited	Oxford BioMedical 2017/2018 lentiviral vector capacity expansion project		£2,998,281

Project description - provided by applicants

Oxford BioMedica (OXB) is a company with broad and global market-leading capabilities in terms of development, manufacture and testing of lentiviral vectors for clinical and commercial use. As a platform/product developer OXB pioneered in vivo delivery of lentiviral vectors, and we have several strategic partnerships, such as one with Novartis supporting the development of chimeric antigen receptor (CAR)-T-cell programmes, including Kymriah[™] which is the only commercially approved product based on lentiviral vector technology. OXB seeks funding in support of a £6m project to help expand our existing GMP manufacturing capacity in the UK. This project is linked into a broader capacity expansion plan that will lead to increased high value manufacturing activities, together with the commitment to create many more highly skilled jobs. OXB continues to develop technologies based on state-of-the-art platform, manufacturing and testing capabilities, and will use the requested funding to further support our market leading position, ensuring the UK continues to lead in many areas of the development of advanced therapies.

Note: you can see all Innovate UK-funded projects here

https://www.gov.uk/government/publications/innovate-uk-funded-projects_Use the Competition Code given above to search for this competition's results